Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339481 · ClinicalTrials.gov registry record
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
A clinical trial, sponsored by Astellas Pharma.
- Completed
- Registry status
- 26
- Enrollment target
NCT01339481 is a clinical trial that has completed, run by Astellas Pharma. The registered enrollment target is 26 participants.
The verdict
NCT01339481 has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
Interventions
- DRUG abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339481
The ClinicalTrials.gov registry entry for NCT01339481 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which abatacept is the first listed.
NCT01339481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339481 about?
NCT01339481 is a clinical study titled "A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept". The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
What is the current status of trial NCT01339481?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2011-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01339481?
The interventions under investigation include: abatacept (DRUG).
Who is sponsoring clinical trial NCT01339481?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.